Loomis Sayles & CO L P Chemo Centryx, Inc. Transaction History

Loomis Sayles & CO L P

$76.2 Billion
Q3 2024

Shares

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2021 Aug 13, 2021	SELL	$9.59 - $50.88 $7.97 Million - $42.3 Million	-831,264 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$49.53 - $68.4 $3.32 Million - $4.59 Million	67,091 Added 8.78%	831,264 $42.6 Million
Q4 2020 Feb 12, 2021	BUY	$47.25 - $65.16 $13.5 Million - $18.7 Million	286,601 Added 60.01%	764,173 $47.3 Million
Q3 2020 Nov 12, 2020	BUY	$46.35 - $61.69 $8.6 Million - $11.4 Million	185,453 Added 63.49%	477,572 $26.2 Million
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $11.3 Million - $19 Million	292,119 New	292,119 $16.8 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.